Apollo Care, Columbia, MO

Is Apollo Care an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Apollo Care in Columbia, MO, first registered Sep 14, 2017 and most recently registered Dec 24, 2025. FDA lists its last inspection as Jul 28, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Columbia, MO
Initial registration
Sep 14, 2017
Most recent registration
Dec 24, 2025
Last inspection
Jul 28, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Apollo Care, LLC, Columbia, MO (FEI number 3013927023), matched to this page by exact name, city and state. It lists 4 inspections: 4 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 27, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139270231268734
Apr 5, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139270231202743
Sep 8, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139270231151240
Mar 13, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139270231044972

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 18 numbered observations in all, across 3 inspections ending Sep 8, 2021 to Jul 28, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 13, 2026 to Jul 28, 2026: 7 observations

Firm on the cover
Apollo Care, LLC, 3801 Mojave Ct. Ste 101, Columbia, MO 65202-4042, USA
FEI number
3013927023
Establishment type on the cover
503B Outsourcing Facility
FDA district office on the cover
8050 Marshall Dr., Suite 205 Lenexa, KS. 66214
Matched to this page by
FEI number on the cover; linked from 503B list, actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure of the quality control unit to secure their responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling. and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated.

Specifically,

A) You do not have procedures for documented review of retain samples. On 07/21/2026 and 07/22/2026 the inspection team reviewed retain samples of Semaglutide Injection and Semaglutide with Glycine Injection drug product vials and observed approximately 59 vials across <Redacted B4> contained white particles of varying size and quantity, of which you were previously unaware.

# of Vials with Observed Particulate

# of Via ls Free of Particulate

Lot#

Product

AC-017115

Semaglutide 4.5mv/mL Injection 12

<Redac

ted B4> >-- AC-017163

Semaglutide 4.5mv/mL lnjection 2 >-- AC--017167

Semaglutide 2.5mg/mL Injection 12

>-- - AC--017170

Semaglutide 4.5mg /mL Injection

- AC-017204

Semaglutide 0.9mg / mL Injection

1 - AC--017225

Semaglutide 2.5mg / mL Injection 12

- AC-017274 ...

Read the full 483 (PDF on fda.gov)

Observation 2

(Repeat)

Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes.

Specifically,

A) On 01/15/26 during aseptic filling operations for Semaglutide 4.5 mg/ml lnjection Lot AC-017 147 the particle counter used in the ISO 5 filling zone was paused during a manual intervention performed to adjust the <Redacted B4> height on the <Redacted B4> aseptic filler in response to a jam. There was no notation in your batch record's Exception Handling Log describing the events leading to, during, and after the intervention. You relied on an after-the-fact incident report to release the batch despite the missing particle count data. You released this batch on 01/23/2026.

4 B) Smoke studies conducted to visualize airflow within the Product Finishing Lab <Redacted B4> automated filling line ISO 5environment indicate turbulent airflow over open <Redacted B4> sterile vials and interrupted first air over <Redacted B4> sterile stoppers. ...

Read the full 483 (PDF on fda.gov)

Observation 3

(Repeat)

There is a failure to thoroughly review any unexplained discrepancy, the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A) Your visual inspection procedure INST00 Visual Inspection Revision 14 Effective Date 02/05/2026 is inadequate in that:

i) Lot tolerance percent defect criteria is inadequate in that you allow for less than or equal <Redacted B4> of rejected units regardless of defect risk classification for all your sterile injectable drug products. You also allow for a greater than <Redacted B4> visual inspection rejection rate if a subsequent reinspection of the remaining unrejected units results in a rejection rate of less <Redacted B4> again regardless of defect risk classification.

ii) "Reflective", "non-reflective", and "agglomeration" particles in the sterile injectable drug products are classified as Minor defects with "no safety/CCI risk" .

B) You failed to investigate multiple differential pressure excursions for classified cleanrooms where aseptic operations are performed. For example: ...

Read the full 483 (PDF on fda.gov)

Observation 4

(Repeat)

Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas.

Specifically,

A) The design of your <Redacted B4> sterile IV bag filling process lacks adequate aseptic and in-process material controls. This process was observed on 07/17/2026 during the compounding of Vancomycin 1.5g added to 250ml of 0. 9% Sodium Chloride (Injection For intravenous Use Only) Lot AC-017291.

i) Unfinished in-process Sodium Chloride IV bags were observed to be unnecessarily moved into and through the ISO 5 aseptic filling environment without aseptic manipulation, only to be removed back into the adjacent ISO 7 environment for intermittent in-process weight checks before being re­introduced into the ISO 5 hood.

ii) A support compounding operator was observed repeatedly handling both unfinished Sodium Chloride IV bags and finished Vancomycin in Sodium Chloride IV bags during in process weight checks, without adequate control over identification of finished and unfinished IV bags.

Observation 5

Each component is not tested for confonnity with all appropriate written specifications for purity, strength, and quality.

Specifically,

A) You do not test all received containers of at-risk API raw material <Redacted B4> or potential contamination within <Redacted B4> and <Redacted B4>. You release raw material <Redacted B4> for compounding sterile human injectable drugs based upon review of the supplier CoA. You use <Redacted B4> a raw material in Semaglutide Injection products, including but not limited lot AC-017165.

B) Your firm releases critical raw materials for use in compounding before a specific identity test. Performance and review of identity testing occur after quality release. You neither require batches to be made exclusively with materials after a completed identity test nor have a process to ensure that compounded lots are withheld from distribution until all component raw materials have a completed identity test. For example, you released semaglutide <Redacted B4> for use in compounding on 01/12/2026. ...

Read the full 483 (PDF on fda.gov)

Observation 6

(Repeat)

Buildings used in the manufacture, processing, packing, or holding of a drug do not have the suitable construction and location to facilitate cleaning, maintenance, and proper operations.

Specifically,

A) On 07/13/2026 the inspection team observed you storing bagged sterile gowning and opened boxes of bagged components and materials used for aseptic compounding including sterile vials, vial stoppers, syringes, sterile <Redacted B4> bag, and IV bags of Sodium Chloride Injection USP in a warehouse constructed with exposed wood and <Redacted B4>, -coated wall insulation. On 07/17/2026, the inspection team observed a non-integral package of sterile coveralls in the facility's prep room amongst sterile garb staged for use in production.

B) A textured wall panel, approximately 4' x 18" in size, was observed on the wall in ISO 8 room Anteroom <Redacted B4> where all bulk formulation is performed.

Observation 7

Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 5038 because they (a) are not used to compound drug products that appear on the drug shortage list in effect under section 506E of the Act and (b) do not appear on a list developed by FDA of bulk drug substances for which there is a clinical need.

Specifically,

Your facility compounded human drug products using semaglutide and tirzepatide bulk drug substance.

Inspection Mar 10, 2025 to Mar 27, 2025: 6 observations

Firm on the cover
Apollo Care, LLC, 3801 Mojave Ct Ste 101, Columbia, MO 65202-4042
FEI number
3013927023
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
8050 Marshall Drive, Suite 205 Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

A) Your quality unit failed to evaluate and approve removal of the hand washing sink from the ISO 8 Hallway/ Anteroom. Facility construction within your ISO classified cleanroom was not conducted per SOP CQI002 Management of Change Authorization (MOCA).

B) Your written procedure, PRC002 Facility Cleaning Procedure, Rev 15, Effective Date 03/01/2025, instructs documentation of <Redacted B4> cycles in Logbook <Redacted B4>. This record of decontamination/cleaning is deficient, such that it does not capture details to demonstrate the specifications of each <Redacted B4> cycle meet those established during performance qualification/ validation. Details of each cycle are instead captured in vendor supplied application software accessed through a mobile device. You lack documented validation showing that the application software that generates and stores details of <Redacted B4> cleaning/decontamination meet Part 11 requirements for electronic records.

Observation 2

AMENDMENT 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A) Your firm lacks assurance that non-sterile in-process bulk drug solutions exposed to cleaning agents during 1SO 8 Anteroom cleaning do not alter the quality and purity of sterile compounded finished drug product produced from exposed bulk drug solution. Your firm performs cleaning of the ISO 8 Hallway/ Anteroom while non-sterile in-process bulk drug solution is stored there.

• On 03/1 8/2025 I observed storage of non-sterile bulk drug solution, Phenylephrine HCL 100 mcg/mL, Lot <Redacted B4> in a Liter beaker loosely covered with aluminum foil in the TSO 8 classified Hallway/ Anteroom during operator gowning and area cleaning. Cleaning agents included sterile sporicidal <Redacted B4> and sanitizer <Redacted B4, I observed your operator repeatedly sprayed a microfiber mop head with cleaning agents near the beaker containing bulk drug solution was <Redacted B4> and filled as finished drug product, Phenylephrine HCL 100 mcg/mL in 10 mL Syringe, Lots <Redacted B4> and <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

AMENDMENT 1

Specifically,

A) Written procedure, PRC002 Facility Cleaning Procedure, Rev 15, states that no high particle shedding materials may enter the cleanroom suite. Your cleaning processes within the ISO classified cleanroom suite include use of disposable sterile polyester cleaning pads and microfiber mop heads, which appeared to be shedding.

• 1) On 3/10/2025 I observed white fiber-like particles and debris on the floor of ISO 7 <Redacted B4> following <Redacted B4> area cleaning that included equipment, ceilings, walls, and floors. ISO 5 <Redacted B4> Laminar Airflow Hoods ) <Redacted B4> where <Redacted B4> of compounded bulk drug products is located in the <Redacted B4>

• On 3/18/2025 I observed white fiber-like. particles on the floor of the ISO 8 Hallway/ Anteroom following area cleaning that included equipment, walls and floors. ...

Read the full 483 (PDF on fda.gov)

Observation 4

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A) Your environmental monitoring recovered mold in ISO classified areas after implementing your firm's Mold Risk Mitigation strategies. Your mitigation strategies include <Redacted B4> of unclassified product storage areas. You have not investigated to determine a root cause for mold found in your ISO classified clean room suite and therefore lack assurance that your mold risk mitigation strategies are effective to ensure that your injection, infusion, and epidural sterile compounded drug products are produced in aseptic conditions. For example,

• On 08/30/2024 environmental monitoring surface sampling found fungi in your unclassified product storage areas, including Alternaria alternata, Acremonium variecolor, Cladosporium cladosporoides, and Fusarium solari.

• On 9/18/2024 environmental monitoring surface sampling ofthe TSO 8 Anteroom recovered 1 cfu fungi (Acremonim variecolor). ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

A) On 03/18/2025, I observed an unsealed and loose ceiling tile within the ISO 7 <Redacted B4> Lab during <Redacted B4> of non-sterile bulk drug solution in the ISO 5 hood, Phenylephrine HCL 100 mcg/mL, Lot <Redacted B4>. During setup and <Redacted B4> of the bulk drug solution, the ceiling tile repeatedly lifted, exposing the room to a lesser quality air that bypassed HEPA filtration. Operator gowning, which was exposed to lesser quality air in the ISO 7, <Redacted B4> Lab, was then worn by the ISO 5 Direct Compounder during syringe fill of Phenylephrine HCL 100 mcg/mL, Lot <Redacted B4>, Exp 09/14/2025.

AMENDMENT 1

Lot._....._.-..__,, During setup and._.-.___.1 ofthe bulk drug solution, the ceiling tile repeatedly lifted, exposing the room to a lesser quality air that bypassed HEP A filtration. Operator gowning, which was exposed to lesser quality air in the ISO 7._....,_.ii.....,Lab, was then worn by the ISO 5 Direct Compounder during syringe fill ofPhenylephrine HCL 100 mcg/mL, Lotm;;;a..._._ __, , Exp 09/14/2025. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction and location to facilitate cleaning, maintenance, and proper operations.

Specifically,

Observation of exposed wood and wall insulation in warehouse storage areas where components and materials used in aseptic areas are stored. These surface[s and] materials are likely to generate particles and may harbor microbiological contamination within material storage areas. Examples of stored materials include: IV bags of normal saline and water for injection, packages holding syringe[s], empty IV bags <Redacted B4> bulk storage bags.

Inspection Sep 8, 2021: 5 observations

Firm on the cover
Apollo Care, LLC, 3801 Mojave Court, Suite 101, Columbia, MO 65202
FEI number
3013927023
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
USFDA 5050 Marshal Dr. Suite 205, Lemeux, 66214 Email Responses To: Program Division Director ORAPHARM3
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. Specifically,

A. During finished product testing, the potency for lot <Redacted B4> of Vancomycin 1 .5g in 500 mL 0.9% Sodium Chloride was found to be 116.1 %, which was above the listed specification of <Redacted B4>. Your investigation report, number CR-19-001, for this OOS lists the preliminary root cause as pump overfill, but then changes to laboratory error based on the <Redacted B4> analysis results. However, the contract laboratory performing the potency testing stated they could not invalidate the original OOS result because the original sample was not stored as directed and could have degraded, which rendered it unfit for an adequate retest. After receiving the OOS results, you submitted <Redacted B4> additional units for potency testing, which came back within specification at 103.0%, 100.7%, and 105.5%. You accepted the resample results and released this lot for distribution on 08/15/2019.

B. During finished product testing, the potency for lot of Norepinephrine 8mg/250mL DSW was found to be 115.2%, which was above the listed specification of <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent objectionable microorganisms in drug products purporting to be sterile are not established, written, and followed.

A. On 08/19/2021, during aseptic filling operations of Vancomycin, 1500mg in 250 mL of Sodium Chloride IV bags, lot <Redacted B4>, I observed your employee using <Redacted B4> to wipe down the medication ports on the bags outside of the ISO 5 hood prior to placing them in the ISO 5 hood in <Redacted B4> Laboratory - which is classified as ISO 7. A second employee; then pierces the medication ports of each bag with a <Redacted B4> needle to add the Vancomycin to the 250 mL of Sodium Chloride without sterilizing the medication port in the ISO S environment.

B. Gowning to enter the ISO 7 area is performed in the ISO 8 Anteroom <Redacted B4>. On <Redacted B4> while observing aseptic filling operations of Vancomycin 1500 mg in 250 mL of Sodium Chloride IV bags, lot <Redacted B4>, we observed employees moved frequentyly between the ISO 7 <Redacted B4> Lab <Redacted B4> and the ISO 8 hallway (Anteroom <Redacted B4> to retrieve other items such as additional Sodium Chloride IV bags. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

A. On S/19/21 during the <Redac ted B4> setup for Bulk Fentanyl Citrate Solution in the <Redacte d B4> Lab the compounding technician did not have any environmentaJ monitori ng in th e LAF <Redacted B4> when making th e connec tion to th e <Redacted B4> assembly. The fi rm did not take active <Redac ted B4> samples during this critical operation. A <Redacted B4> plate was added only after ster ile b ulk receiving bag was att ach ed to the <Redacted B4> side (sterile side) of the <Redacted B4>. In addition, the firm had no nonviable p articul ate monitoring in the ISO 5 throughout all operations for <Redacted B4> of this bu lk. The bulk Sterilized Drug product solut ion was used to make Fentanyl Citrate, 50 mcg/mL in 50 mL syringes, lot <Redacted B4>.

B.

On <Redacted B4>, during the compounding of Fentanyl Citrate, 50 mcg,'mL in 50 mL syringes, lot <Redacted B4>, I observed your employee perform the aseptic connection of the bulk bag of Fentanyl Citrate solution to the pump on the far left-side of the ISO 5 hood in <Redacted B4> Laboratory. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic Processing areas are deficient in that the floors, walls, ceilings, and work surfaces are not smooth and/or hard surfaces that are easily cleanable. Specifically,

THIS OOCUI.ENT LISTS OSSERVATIONS MADE BV THE FDA REPRESEITTA llVE(S) DURING THE INSPECTION OF YOUR f'ACIUlV. THEY Alli: INSPECT!ONAL OIISERVATIOHS; ANO 00 NOT REPRESENT A FlNAl AGENCY DETERMIW.TION RE~NG YOUR COMPUANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPI.EMENTEO, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE 08JECTIOH OR ACTION~ THE FDA REPRESEHTA TIVE(S) OURlNG THE INSPECTION OR SU91.tT THIS INFORMATION TO FOA AT THE AOOIU:SS ABOVE. IF YOU HAVE AHY QUESTIOOS, Pl.EASE CONTACT FDA ATTHE PHONE NUMBER ANO ADO RESS ABOVE, The obNrvaUont nowd In th1- Fonn FDA 4H are not an exhau.tlve Ii.ting of obJK1I0111ble c.ondltlona. Under tile law, your firm la l'Npo,.lble for conducting lnt.nwl Mlf-audlta to Identify and c:orrec:t any and all violations of the quality eystam requirements.

0\/RJNG AH INSPECTION OF YOUR FIRM (l)(WE) 08SERVEO:

A. On 08/17/2021, we observed:

1. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the <Redacted B4> process. Specifically,

A. Your firm's current laminar airflow studies (smoke studies) of the ISO 5 Horizontal Laminar Airflow Workstations were not performed under conditions showing aseptic operations that are representative of your current compounding practices nor did they emulate all critical unit operations and interventions used during compounding of your sterile drug products.

compounding practices nor did they emulate all critical unit operations and interventions used during compounding of your sterile drug products.

B. Media FiJI Records for Family ll (Batch(b) (4) and Family m (Batch(6) (4) do not accurately represent cunent manufacturing practices in that:

l. Your finn receives 6 4 that are not connected to the (b) (4) connected to the tubing both D (4 and 15 (4 of the 6)(4) . Connections of th~(6)(4) to the (6) (4) bag used as the receiving vessel for the sterilized bulk product represent a possible route of microbial contamination. ...

Read the full 483 (PDF on fda.gov)

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Apollo Care). That is not a finding beyond this index’s search.

The Apollo Care pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 8 products naming semaglutide and tirzepatide under the labeler name “Apollo Care, LLC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (8). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
71170-495Semaglutide 12.5 mgSemaglutide 12.5 mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-640Semaglutide 1mg and Cyanocobalamin 0.5mgSemaglutide 1mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-650Semaglutide 2.5mg and Cyanocobalamin 0.5mgSemaglutide 2.5mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-690Semaglutide 12.5mg and Cyanocobalamin 2.5mgSemaglutide 12.5mg and Cyanocobalamin 2.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-811Semaglutide 2.25 mgSemaglutide 2.25 mgINJECTION, SOLUTIONSUBCUTANEOUS.9 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-821Semaglutide 6.75 mgSemaglutide 6.75 mgINJECTION, SOLUTIONSUBCUTANEOUS4.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-610Tirzepatide 20mg and Pyridoxine 8mgTirzepatide 20mg and Pyridoxine 8mgINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-630Tirzepatide 60mg and Pyridoxine 12mgTirzepatide 60mg and Pyridoxine 12mgINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.